InvestorsHub Logo
Followers 1
Posts 26
Boards Moderated 0
Alias Born 02/22/2020

Re: Fmello post# 6931

Friday, 06/18/2021 8:56:54 AM

Friday, June 18, 2021 8:56:54 AM

Post# of 7488
I guess the following:

- Outpatient: CMS C code - October 2021. Latest Jan 2022. Commercial launch H1 2022.
- Vitiligo: Full recruitment H2 2021. Trial Results H2 2022. FDA approval mid 2023
- Trauma: Recruitment H2 2022. Results H1 2023. FDA approval late 2023 - early 2024
- Japan approval: H2 2021
- Proof of concept for E.B: H2 2021
- Proof of concept on skin for rejuvenation: H2 2021. Commence feasibility study H2 2021.
- Sales: continue to substantially increase QoQ as they gain market share (excluding BARDA)
- Patents?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RCEL News